Cargando…
Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease
As biologic, epidemiologic, and clinical trial data have demonstrated, inflammation is a key driver of atherosclerosis. Circulating biomarkers of inflammation, including high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6), are associated with increased risk of cardiovascular events...
Autores principales: | Aday, Aaron W., Ridker, Paul M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403155/ https://www.ncbi.nlm.nih.gov/pubmed/30873416 http://dx.doi.org/10.3389/fcvm.2019.00016 |
Ejemplares similares
-
Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond
por: Aday, Aaron W., et al.
Publicado: (2018) -
Atherosclerotic cardiovascular diseases in inflammatory bowel diseases: to the heart of the issue
por: Gabbiadini, Roberto, et al.
Publicado: (2023) -
Inflammatory Mediators in Atherosclerotic Vascular Remodeling
por: Evans, Bryce R., et al.
Publicado: (2022) -
Editorial: Conduction system pacing: What’s missing for the paradigm shift?
por: Marcantoni, Lina, et al.
Publicado: (2023) -
Coronary Atherosclerotic Disease and Cancer: Risk Factors and Interrelation
por: Li, Jinjing, et al.
Publicado: (2022)